Zhejiang Jianfeng Group announced that its wholly-owned subsidiary Jianfeng Pharmaceutical learned of the results of the pharmaceutical GMP compliance inspection from the Zhejiang Provincial Drug Administration website (Zhe 2024 No. 0226). Jianfeng Pharmaceutical's BFS eye drop production line in the formulation workshop met the requirements of the "Good Manufacturing Practice for Pharmaceutical Products" (2010 revision) during the inspection conducted from July 19 to July 23, 2023. The products that passed this inspection include Olopatadine Hydrochloride Eye Drops and Sodium Hyaluronate Eye Drops.